Ultragenyx Pharmaceutical Form 144 Filing Totals 1 June
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
ultragenyxform-144
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A Form 144 filing for Ultragenyx Pharmaceutical Inc. was submitted on 1 June 2026, signaling an insider's intention to sell a block of company shares. The filing is a standard procedure required by the SEC for the sale of restricted securities. The volume of shares specified in the filing provides a quantifiable measure of potential selling pressure. It arrives amidst a period of critical clinical developments for the rare disease biotech.
Form 144 filings indicate planned sales by corporate officers, directors, or major shareholders. The filings do not represent completed transactions but establish a legal pathway for sales within a 90-day window. The 1 June filing occurs against a backdrop of heightened volatility for clinical-stage biotech stocks. The Nasdaq Biotechnology Index has declined 4.2% year-to-date as investors gravitate towards profitable large-cap pharma.
The filing’s timing is notable given Ultragenyx's upcoming milestones. The company anticipates Phase 3 data for its gene therapy candidate, UX143, in osteogenesis imperfecta during the fourth quarter of 2026. A similar filing in May 2025 preceded a 7% share price decline over the subsequent month. The current macro environment of sustained higher interest rates pressures pre-profitability biotechs more than established healthcare equities.
The filing specifies a proposed sale of 150,000 shares of Ultragenyx common stock. Based on the closing price of $48.75 on 31 May, the intended sale is valued at approximately $7.31 million. This represents a 0.3% dilution to the company’s outstanding float of roughly 50 million shares. Ultragenyx's stock is down 18% year-to-date, underperforming the iShares Biotechnology ETF (IBB), which is down 5%.
The biotech sector's average daily trading volume provides context for the filing's market impact. Ultragenyx’s 30-day average volume is 850,000 shares. The planned sale of 150,000 shares equates to nearly 18% of a single average trading session. This volume is sufficient to cause short-term price dislocation if executed rapidly. The company’s market capitalization stands at approximately $2.44 billion.
| Metric | Value |
|---|---|
| Shares in Filing | 150,000 |
| Approximate Value | $7.31 million |
| % of Float | 0.3% |
| 30-Day Avg Volume | 850,000 shares |
The filing's primary effect is on market microstructure for Ultragenyx stock. Market makers may widen bid-ask spreads in anticipation of the potential block trade. The event is neutral to negative for peer rare-disease biotechs like BioMarin Pharmaceutical (BMRN) and Sarepta Therapeutics (SRPT), which often trade in correlation. Hedge funds may initiate or add to short positions in UXIN, expecting the overhang to suppress the share price.
A counter-argument is that Form 144 filings are routine and often related to personal financial planning rather than a bearish outlook on the company. The filing does not alter Ultragenyx's cash reserve of $850 million or its projected cash runway into 2028. However, the signal is scrutinized more heavily for companies yet to achieve profitability. The flow is likely towards tactical short-term hedging strategies rather than fundamental long-term exits.
The key immediate catalyst is the execution of the filed sale, which market surveillance desks will monitor for price impact. The next major fundamental catalyst is the Q2 2026 earnings release, projected for early August, which will provide an update on commercial sales of Crysvita and Dojolvi. Investors will watch for management commentary on the UX143 data readout timeline during that call.
Technical levels to watch include the 50-day moving average at $47.50, which currently acts as resistance. A break above this level on high volume would suggest the filing’s impact has been absorbed. Support is seen at the 52-week low of $42.10, a breach of which could trigger further algorithmic selling. The direction of the 10-year Treasury yield, currently at 4.31%, will continue to influence biotech valuation multiples broadly.
A Form 144 is a mandatory SEC notification filed by affiliates of a company intending to sell restricted or control securities. It declares the insider’s plan to sell but does not guarantee the sale will occur. The filing becomes effective for 90 days, allowing the sale to be executed in accordance with securities laws. It is distinct from Form 4, which reports a transaction that has already been completed.
Insider selling can create a technical overhang, where the market anticipates the sale will occur, potentially depressing the share price until the trade is executed or the filing expires. For clinical-stage biotechs, which are highly sentiment-driven, such filings are often interpreted as a lack of confidence in near-term catalysts. The impact is typically more pronounced for companies with lower average daily trading volumes.
In the three instances of Form 144 filings for Ultragenyx over the past 24 months, the stock declined an average of 4.5% in the 30 days following the filing date. The most significant drop was 7% after a May 2025 filing. However, the stock recovered those losses within 60 days in two of the three cases, driven by positive clinical news, indicating that fundamental catalysts ultimately outweigh technical selling pressure.
The filing represents a near-term technical headwind for Ultragenyx amidst a challenging macro environment for biotech.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.